COVID-19 global death toll nears seven million, WHO says ‘still a threat’
HQ Team October 2, 2023: A total of 770,875,433 (770.8 million) people globally have been infected by the coronavirus as of September 27.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team October 2, 2023: A total of 770,875,433 (770.8 million) people globally have been infected by the coronavirus as of September 27.
HQ Team September 29, 2023: DIOSynVax, a spin-out company of the University of Cambridge, is in its final stage of human trials of.
The Central Intelligence Agency offered bribes to six analysts to change their position on COVID-19’s origins from a lab leak theory in China.
HQ Team September 13, 2023: The US national public agency has recommended a COVID-19 vaccination policy where updated shots are given starting from.
HQ Team September 11, 2023: A total of 34 confirmed cases of the COVID-19 virus variant, BA.2.86, have been identified in the UK,.
HQ Team September 6, 2023: Britain’s Medicines and Healthcare products Regulatory Agency has cleared a vaccine made by Pfizer Inc., and its German.
HQ Team September 3, 2023: The jury is still out on which virus causes chronic fatigue syndrome, its diagnosis, the treatment options, and.
HQ Team August 25, 2023: SARS-CoV-2 can damage organs such as the heart, brain, kidney, and blood vessels and not the lungs alone,.
HQ Team August 21, 2023: The UK reported its first variant of COVID-19 virus, BA.2.86, three days ago, which suggests “a degree of.
HQ Team August 1, 2023: The US medical research agency has opened enrollment for the second stage of trials to evaluate about four treatments.